Anugerah 88 Logo
$12.35-0.37|(-2.91%)
52W H: 20.952W L: 12.63Beta: 0.77

About Amarin Corporation PLC

Frequently Asked Questions

What is the 52-week range for AMRN?

The 52-week high is $20.9 and the 52-week low is $12.63.

What is the P/E ratio for AMRN?

The P/E ratio data is currently unavailable.

What is the dividend yield for AMRN?

This company does not currently pay a dividend or the data is unavailable.

What is the Return on Equity (ROE)?

The trailing twelve months (TTM) Return on Equity is -5.99%.

What is the Net Profit Margin?

The Net Profit Margin (TTM) is -14.20%.

What is the Price to Book (P/B) Ratio?

The annual Price to Book ratio stands at 0.61.

Analyst Recommendation Trends

Wall Street analyst consensus for AMRN over the last few months:

2026-09-01
Buy: 0
S.Buy: 0
Hold: 2
Sell: 3
2026-08-01
Buy: 0
S.Buy: 0
Hold: 2
Sell: 2
2026-07-01
Buy: 0
S.Buy: 0
Hold: 3
Sell: 2
2026-06-01
Buy: 0
S.Buy: 0
Hold: 3
Sell: 2

Latest AMRN News

Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study

MRK's tulisokibart meets the phase IIb HS study's primary endpoint, with high and medium-dose regimens showing superiority over placebo at week 16.

Yahoo10/1/2026

Teva's Branded Drugs Take Center Stage in Its Growth Strategy

Teva's branded drugs are driving stronger growth as Austedo, Ajovy and Uzedy gain momentum and its pipeline of new candidates expands.

Yahoo9/29/2026

RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study

Roche's Lunsumio-Revlimid combo meets its study goal in second-line or later follicular lymphoma, improving PFS versus rituximab plus Revlimid.

Yahoo9/17/2026

RCKT Aligns With FDA on Completing Phase II Study in Danon Disease

Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.

Yahoo9/16/2026

Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?

Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo9/10/2026

Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?

Here is how Amarin (AMRN) and Royalty Pharma (RPRX) have performed compared to their sector so far this year.

Yahoo9/9/2026

Related Stocks (Peers)

Companies operating in similar sectors to AMRN:

ALKSPRTAAMRN

Recent Insider Transactions

DateNameShares ChangedPriceValue
2026-08-01Fishman Peter L.+313--
2026-08-01Fishman Peter L.-155$14.26$2,210
2026-08-01Fishman Peter L.+313--
2026-07-01Keenan David Paul+3,688--
2026-07-01Keenan David Paul-1,926$15.94$30,700
2026-07-01Keenan David Paul+3,688--
2026-07-01Fishman Peter L.+2,447--
2026-07-01Fishman Peter L.-1,206$15.94$19,224
2026-07-01Fishman Peter L.+2,447--
2026-07-01Provoost Jonathan+3,688--
2026-07-01Provoost Jonathan-1,264$15.94$20,148
2026-07-01Provoost Jonathan+3,688--
2026-07-01Ketchum Steven B+3,688--
2026-07-01Ketchum Steven B-1,887$15.94$30,079
2026-07-01Ketchum Steven B+3,688--
2026-04-18Bonfiglio Patrice Eadon+838--
2026-04-18Bonfiglio Patrice Eadon-403$14.98$6,037
2026-04-18Bonfiglio Patrice Eadon+838--
2026-04-18O'Connor Oliver+838--
2026-04-18O'Connor Oliver-438$14.98$6,561
2026-04-18O'Connor Oliver+838--
2026-04-18Cohen Paul+838--
2026-04-18Cohen Paul-403$14.98$6,037
2026-04-18Cohen Paul+838--
2026-04-18Sullivan Diane E.+838--
2026-04-18Sullivan Diane E.-403$14.98$6,037
2026-04-18Sullivan Diane E.+838--
2026-04-18Sterling Louis III+838--
2026-04-18Sterling Louis III-403$14.98$6,037
2026-04-18Sterling Louis III+838--
2026-04-18Horn Keith+838--
2026-04-18Horn Keith-403$14.98$6,037
2026-04-18Horn Keith+838--
2026-04-18Odysseas Kostas D+838--
2026-04-18Odysseas Kostas D-403$14.98$6,037
2026-04-18Odysseas Kostas D+838--
2026-04-01Fishman Peter L.+125--
2026-04-01Fishman Peter L.-62$14.46$897
2026-04-01Fishman Peter L.+125--
2026-02-01Keenan David Paul+30,060--
2026-02-01Keenan David Paul+8,013--
2026-02-01Fishman Peter L.+27,750--
2026-02-01Fishman Peter L.+6,167--
2026-02-01Provoost Jonathan+36,060--
2026-02-01Provoost Jonathan+8,013--
2026-02-01Berg Aaron+120,566--
2026-02-01Berg Aaron+26,793--
2026-02-01Ketchum Steven B+36,060--
2026-02-01Ketchum Steven B+8,013--
2026-01-31Keenan David Paul+1,933--
2026-01-31Keenan David Paul+2,246--
2026-01-31Keenan David Paul-1,010$15.42$15,574
2026-01-31Keenan David Paul+1,933--
2026-01-31Keenan David Paul-1,173$15.42$18,088
2026-01-31Keenan David Paul+2,246--
2026-01-31Fishman Peter L.+1,833--
2026-01-31Fishman Peter L.+563--
2026-01-31Fishman Peter L.-1,008$15.42$15,543
2026-01-31Fishman Peter L.+1,833--
2026-01-31Fishman Peter L.-310$15.42$4,780
2026-01-31Fishman Peter L.+563--
2026-01-31Berg Aaron+1,933--
2026-01-31Berg Aaron+2,246--
2026-01-31Berg Aaron-1,063$15.42$16,391
2026-01-31Berg Aaron+1,933--
2026-01-31Berg Aaron-1,235$15.42$19,044
2026-01-31Berg Aaron+2,246--
2026-01-31Ketchum Steven B+1,933--
2026-01-31Ketchum Steven B+2,246--
2026-01-31Ketchum Steven B-1,062$15.42$16,376
2026-01-31Ketchum Steven B+1,933--
2026-01-31Ketchum Steven B-1,235$15.42$19,044
2026-01-31Ketchum Steven B+2,246--
2026-01-02Keenan David Paul+3,688--
2026-01-02Keenan David Paul-1,926$13.96$26,887
2026-01-02Keenan David Paul+3,688--
2026-01-02Fishman Peter L.+2,447--
2026-01-02Fishman Peter L.-1,356$13.96$18,930
2026-01-02Fishman Peter L.+2,447--
2026-01-02Provoost Jonathan+3,688--
2026-01-02Provoost Jonathan-1,488$13.96$20,772
2026-01-02Provoost Jonathan+3,688--
2026-01-02Ketchum Steven B+3,688--
2026-01-02Ketchum Steven B-2,041$13.96$28,492
2026-01-02Ketchum Steven B+3,688--